Nectar Lifesciences Announces FY2025-26 Results Amid Slump Sale of Core Businesses
Nectar Lifesciences Limited released its audited financial results for the fiscal year (FY) 2025-26, detailing significant transactions, including the slump sale of several core business units. The Company also announced the successful completion of a share buy-back and outlined governance updates, including proposals for Independent Director re-appointments and amendments to internal policies.At its Board meeting held on May 30, 2026, the Company approved the release of audited Standalone and Consolidated Financial Results for the quarter and the full year ended March 31, 2026. The reports, along with Cash Flow Statements and Statements of Assets and Liabilities, reflect the company's operational activities during the period.
Financial Highlights and Transactions
The Company's financial statements indicate substantial transactions classified as discontinued operations, contributing significantly to the financial outcomes for the year ended March 31, 2026. These operations included the Pharma Businesses, Menthol Assets, and the Capsule Business.The total profit before tax from discontinued operations for the full year was reported as (53,765.51) lakhs, contrasting with a profit before tax from continuing operations of (8,786.99) lakhs. An exceptional item gain on slump sale of the Pharma Businesses contributed 16,337.32 lakhs to the results.
The Company also executed a buy-back of equity shares, undertaking the repurchase of up to 3,00,00,000 fully paid-up equity shares of ₹ 1 each at ₹ 27.00 per share, totaling ₹ 8,100.00 lakhs.
The Company disclosed that volatile financial markets and geopolitical developments adversely impacted investments, resulting in a loss of ₹ 5,209.53 lakhs, which was recognized in the Statement of Profit and Loss.
Financial Results Summary (₹ in Lakhs)
| Particulars | Quarter Ended 31-Mar-26 (Standalone Audited) | Year Ended 31-Mar-26 (Standalone Audited) |
|---|---|---|
| Total Income | 758.00 | 929.09 |
| Total Expenses | 6,449.96 | 9,716.08 |
| Profit/(Loss) before exceptional items and tax from continuing operations | (5,691.96) | (8,786.99) |
| Total Profit for the period | (6,791.80) | (29,288.48) |
| Total Comprehensive Income for the period | (6,783.88) | (29,280.56) |
A comparative view of the Consolidated Financial Results for the period is provided below:
| Particulars | Quarter Ended 31-Mar-26 | Year Ended 31-Mar-26 |
|---|---|---|
| Total Income (I + II) | 758.00 | 929.09 |
| Total Expenses (IV) | 6,450.86 | 9,716.98 |
| Total Profit for the period | (6,792.42) | (29,289.10) |
Strategic Divestitures and Operations
The Company completed the sale of multiple business units as part of its strategic plan to optimize non-core assets and strengthen its liquidity.Key transactions under discontinued operations include:
- Pharma Businesses: The Active Pharmaceutical Ingredients business and the Formulation business were transferred to Ceph Lifesciences Private Limited on a going concern basis via a slump sale, finalized for a consolidated consideration of ₹ 125,398.55 lakhs. Of this amount, ₹ 118,798.55 lakhs was received by March 31, 2026, with the remainder of ₹ 6,600.00 lakhs receivable.
- Menthol Assets: Assets related to the menthol business were transferred to Ceph for a consideration of ₹ 2,000.00 lakhs.
- Capsule Business: The Empty Hard Gelatin Capsule business was slated for a slump sale to Capnest Health Care Private Limited for a consideration of ₹ 1,990.00 lakhs.
The company also confirmed its continued assessment of other assets, including the Jammu Unit and vacant land near Garhshankar, Punjab, for potential monetization.
Governance and Corporate Structure Updates
On the governance front, the Board of Directors approved the proposal for the re-appointment of Independent Directors. Dr. Kuldip Kumar Bhasin is proposed for a second consecutive term of five years, effective from September 21, 2026. Separately, Dr. Indu Pal Kaur is proposed for a second term of five years, effective from August 02, 2027.Furthermore, the Company confirmed that KFin Technologies Limited continues to serve as the Registrar and Transfer Agent (RTA), following the withdrawal of the proposal for Alankit Assignments Limited.
The Company also updated its operational policies, amending the Materiality of Information Policy, Related Party Transaction Policy, and Code of Conduct for Prevention of Insider Trading.
In its Statement of Assets and Liabilities, total assets stood at (Rs. in Lakhs):
| Asset Category | Standalone As at 31-Mar-26 | Consolidated As at 31-Mar-26 |
|---|---|---|
| Total non-current assets | 32,692.20 | 33,278.42 |
| Total current assets | 24,956.81 | 25,296.83 |
| Total assets | -61,234.40 | 62,160.64 |
Overall, the audited financial results and associated governance decisions were reported by Nectar Lifesciences Limited on May 30, 2026.
NECLIFE Stock Price Movement
On Friday, Nectar Lifesciences Limited shares slipped 0.32% to settle at ₹12.45. The stock traded on 129,996 shares, finding support within a range defined by a day low of ₹12.25 and a high of ₹12.70.Disclaimer: Due care and diligence have been taken in compiling and presenting news and market-related content. However, errors or omissions may arise despite such efforts.
The information provided is for general informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any securities. Readers are advised to rely on their own assessment and judgment and consult appropriate financial advisers, if required, before taking any investment-related decisions.
Any views, opinions, or statements expressed, where applicable, are those of the respective analysts or experts and do not reflect the views of this website. The website has no association with such viewpoints and does not assume any responsibility for them.
Last edited by a moderator: